News Summary

Montreal-based biotech company Morphocell Technologies has announced the completion of its Series A funding round, securing a total of $50 million USD. This latest funding, co-led by Investissement Québec and Italy’s CDP Venture Capital, adds an additional $10 million USD to the initial $40 million USD raised earlier. The funding will support the expansion of Morphocell’s manufacturing capacity and team, the opening of its first European office in Italy, and the advancement of its flagship ReLiver program aimed at providing an alternative to liver transplants through stem cell-derived therapy. Morphocell’s expansion into Italy, facilitated by CDP Venture Capital’s investment, aims to leverage local talent and research infrastructure to strengthen the company’s global presence in regenerative medicine.